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Abstract
Purpose—To compare the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or opioids 
to the use of acetaminophen without NSAIDs or opioids with respect to associations with birth 
defects.
Methods—We used data from the National Birth Defects Prevention Study (1997–2011). 
Exposure was self-reported maternal analgesic use from the month before through the third month 
of pregnancy (periconceptional). Adjusted odds ratios (aORs) were calculated to examine 
associations with 16 birth defects.
Results—Compared to acetaminophen, mothers reporting NSAIDs were significantly more 
likely to have offspring with gastroschisis, hypospadias, cleft palate, cleft lip with cleft palate, cleft 
lip without cleft palate, anencephaly, spina bifida, hypoplastic left heart syndrome, pulmonary 
valve stenosis, and tetralogy of Fallot (aOR range, 1.2–1.6). Opioids were associated with 
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tetralogy of Fallot, perimembranous ventricular septal defect, and ventricular septal defect with 
atrial septal defect (aOR range, 1.8–2.3), whereas use of both opioids and NSAIDs was associated 
with gastroschisis, cleft palate, spina bifida, hypoplastic left heart syndrome, and pulmonary valve 
stenosis (aOR range, 2.0–2.9).
Conclusions—Compared to periconceptional use of acetaminophen, selected birth defects 
occurred more frequently among infants of women using NSAIDs and/or opioids. However, we 
could not definitely determine whether these risks relate to the drugs or to indications for 
treatment.
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Introduction
Chronic and acute nonobstetric pain during pregnancy is common and can arise from 
prepregnancy maternal conditions such as sickle cell disease, arthritis, headache, injury, and 
surgery (collectively affecting up to 25% of pregnant women [1–5]), as well as pregnancy-
related conditions such as lower back pain and pelvic pain (together affecting 22%–72% of 
pregnant women [6,7]). The selection of safe and effective pain management strategies 
during pregnancy is challenging [8,9]. Early embryonic exposure to certain pain medications 
can result in potentially harmful effects on the fetus [9,10]. Alternatively, fear about the use 
of drugs during pregnancy, both substantiated and unfounded, can lead to undertreatment of 
pregnant women for painful conditions; comorbidities due to inadequate pain management 
can also be harmful to the fetus [8,9,11,12].
Analgesic use during pregnancy is estimated to range from approximately 50% to 80% 
[13,14], with the majority of use occurring during the first trimester, which is of particular 
concern due to potential teratogenic risk during the period of organogenesis [15]. Some of 
the most commonly used analgesics for pain management in the first trimester include 
acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids (reported first 
trimester use in 41%–59% [14,16], 8%–24% [14,17,18], 2%–11% [19,20], respectively). 
Previous studies have examined teratogenic effects of analgesic use during the first trimester, 
and while acetaminophen is generally considered safe in regard to teratogenicity, findings 
for NSAIDs and opioids have been inconsistent [9,11,12,21].
Research is needed to comparatively assess the safety of these analgesics to help guide the 
treatment of pain in pregnancy [9,22]. The objectives of our study were (1) to document the 
prevalence and patterns of self-reported use of acetaminophen, NSAIDs, and opioids during 
pregnancy and (2) to compare the use of early pregnancy NSAIDs and/or opioids to 
acetaminophen with respect to associations with selected birth defects.
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Materials and methods
The National Birth Defects Prevention Study (NBDPS) was a population-based, multisite, 
case-control study of more than 30 major structural birth defects across 10 centers in the 
United States (Arkansas, California, Georgia, Iowa, Massachusetts, North Carolina, New 
Jersey, New York, Texas, and Utah). Birth defect cases, including live born, stillborn, and 
induced abortions, were identified by each Center’s birth defects registry, excluding cases 
with a known cause (e.g., chromosomal or genetic disorders). Live-born controls were 
randomly selected from birth certificates or birth hospitals in the same region and month of 
birth as cases. The specifics of study selection and case classification have been detailed in 
previous publications [23,24].
Eligible cases and controls were interviewed in English or Spanish from 6 weeks to 24 
months after the estimated date of delivery (EDD), with participation of 67% among cases 
and 65% among controls. Before the interview, participants were mailed pregnancy 
calendars to assist in accurate reporting of medication use timing. Mothers were asked about 
conditions such as diabetes, high blood pressure, seizures, respiratory illnesses, infections, 
fevers, chronic diseases, injuries, and surgeries from 3 months before conception (B3) 
through the end of pregnancy (P9). In each of those questionnaire sections, mothers were 
asked about medications they took for treatment of those conditions; in addition, they were 
encouraged to report any additional prescription or nonprescription medications. All 
medications reported were compiled and coded using the Slone Drug Dictionary, which 
links drug products to their active ingredients [25]. Informed consent was obtained from all 
participants, and all protocols, materials, and interview content were approved by the 
Centers for Disease Control and Prevention and local Institutional Review Boards for each 
center.
To best address the two objectives of the study, we used different gestational periods of 
exposure for analyses of patterns of analgesic use (descriptive analysis) and analyses for 
estimating odds ratios (comparative analysis). For the descriptive analysis, we defined 
analgesic use in pregnancy as the use of acetaminophen, NSAIDs, or opioids in B3–P9. In 
our comparative analysis, we defined periconceptional analgesic use as use from 1 month 
before conception (B1) through the third month of pregnancy (P3). Because many over-the-
counter analgesics are predominantly available in combination with other medications [26], 
all exposure groups included individual analgesic products and products in combination with 
nonanalgesics. Because many women used both NSAIDs and acetaminophen and because 
many opioid products include acetaminophen [8,15,27], we created mutually exclusive 
categories of exposure: (1) NSAIDs without opioids (with or without acetaminophen); (2) 
opioids without NSAIDs (with or without acetaminophen); (3) both opioids and NSAIDs 
(with or without acetaminophen); and (4) acetaminophen (without NSAIDs or opioids). As a 
subanalysis, we further stratified the exposures into mutually exclusive groups based on the 
most commonly reported specific medications: NSAIDs into ibuprofen, aspirin, and 
naproxen; and opioids into hydrocodone and codeine.
In all analyses, we excluded mothers with pregestational diabetes, self-reported heroin or 
opioid abuse in B3–P9, missing medication information or dates of use, or who had used a 
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known teratogen (i.e., misoprostol, methotrexate, mycophenolate mofetil, thalidomide, 
isotretinoin, warfarin, or valproic acid [28]) in B3–P9. In comparative analyses, we 
additionally excluded mothers who did not use an analgesic periconceptionally, did not 
report analgesic type, or reported analgesic use “as needed” in B3–P9 without specifying 
timing. We analyzed cases and controls with pregnancies ending on or after October 1, 1997, 
to EDDs on or before December 31, 2011. Potential covariates were identified a priori and 
included maternal age at delivery (continuous; <20 years, 20–34 years, ≥ 35 years), race/
ethnicity (non-Hispanic white, other), prepregnancy body mass index (≥30 kg per m2, <30 
kg per m2), previous live birth (≥1, 0), maternal education (<12 years, ≥12 years), study 
location, EDD year (1997–2001, 2002–2006, 2007–2011), and the following dichotomous 
variables: folic acid consumption B1 through the first month of pregnancy (P1), 
periconceptional alcohol, smoking, and antibiotic use (to better account for analgesic use as 
a result of a possible infection), and infant sex. We used χ2, Fisher’s exact, and two-sample 
t-tests to assess whether these factors varied significantly by analgesic exposure among 
mothers of control infants.
We used logistic regression to estimate crude and adjusted odds ratios and 95% confidence 
intervals for the association between birth defects and use of NSAIDs, opioids, and both 
opioids and NSAIDs, compared to acetaminophen use. Acetaminophen was selected for 
comparison due to previous assessments of its general safety in the first trimester in relation 
to birth defects [16] and from exploratory analyses using this study’s data (Supplemental 
Table 1). Covariates with significant associations with analgesic exposures were included in 
the adjusted model. As this study builds on previous work using the same data source, birth 
defects of interest were selected based on positive associations with one or more of the 
analgesics of interest noted in previous studies [10,14,18,19,22,26,29–32]. Statistical 
significance was set at P < .05, and all analyses were conducted using SAS 9.3 (Cary, NC).
We conducted a number of sensitivity analyses based on excluding certain groups from the 
main comparative analysis, including (1) periconceptional surgery, (2) injury, or (3) fever; 
(4) selected chronic conditions; (5) a family history of birth defects in a first degree relative; 
and (6) periconceptional use of selected common nonanalgesics. Furthermore, we (7) limited 
outcomes to isolated cases (with only one major defect diagnosed), (8) limited analyses to 
women reporting wanting to become pregnant, and (9) restricted to mothers with 6 
(minimum) to 42 (median) weeks between EDD and interview to address potential recall 
bias. In addition, because of the increasing prevalence of gastroschisis [33], especially 
among younger (<20 years) mothers, we assessed whether there was interaction between 
maternal age at delivery (<20, assessed whether there was interaction between maternal age 
at delivery (<20, ≥20 years) with analgesic exposure and gastroschisis in offspring. 
Moreover, to better understand the differences between the opioid exposure group and the 
both opioids and NSAIDs exposure group, we explored whether there were differences in 
reporting by questionnaire section in which opioids were reported.
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Results
Descriptive analysis
Among 29,078 case and 10,962 control mothers meeting our initial inclusion criteria for the 
descriptive analysis, 81% of cases and 80% of controls reported analgesic use in B3–P9, 
with 57% of cases and 54% of controls reporting periconceptional analgesic use (Figs. 1 and 
2). Acetaminophen use increased slightly from B1–P1 and decreased before delivery 
(ranging in B3–P9 between 42% and 47% among cases and 39% and 46% among controls). 
NSAID use was highest during the 3 months before pregnancy and decreased drastically 
from B1–P3 (dropping from 30% to 11% among cases and 24% to 10% among controls). 
Opioid use was consistent throughout pregnancy (at 1% in B3–P9 for both cases and 
controls). Most mothers reporting acetaminophen did so as their only analgesic (58%), 
whereas most mothers reporting NSAID, opioids, or both also reported using acetaminophen 
(70%, 45%, and 46%, respectively) (Supplemental Table 2).
Comparative analysis
Based on positive associations observed in previous literature [10,14,18,19,22,26,29–32], 16 
birth defect case groups of interest were identified and included in our comparative analysis, 
involving 9179 case and 5944 control mothers who reported analgesics periconceptionally. 
The exposed and comparison groups for analyses were made up of 48% of case (54% of 
control) mothers reporting acetaminophen, 48% (42%) NSAIDs, 2% (2%) opioids, and 2% 
(1%) both opioids and NSAIDs. Among mothers who used NSAIDs, 71% (72%) reported 
ibuprofen, 9% (9%) reported aspirin, and 6% (7%) reported naproxen. Among mothers who 
used opioids, 38% (26%) reported hydrocodone and 29% (27%) reported codeine.
Compared to control mothers who reported acetaminophen use, those reporting NSAID use 
were significantly more likely to be older at delivery, non-Hispanic white, nulliparous, high 
school graduates, report periconceptional alcohol and smoking, have a different study 
location, and have a later EDD year; those who reported opioid use were significantly more 
likely to be non-Hispanic white, report periconceptional smoking and antibiotic use, and 
have a later EDD year; and those who reported both opioids and NSAIDs were significantly 
more likely to be older at delivery, non-Hispanic white, high school graduates and report 
periconceptional smoking and antibiotic use (Table 1).
Compared to mothers who reported acetaminophen use, use of NSAIDs was significantly 
associated with seven non-heart and three heart defects in the offspring: gastroschisis, 
hypospadias, orofacial clefts, anencephaly and craniorachischisis, spina bifida, hypoplastic 
left heart syndrome, pulmonary valve stenosis (PVS), and tetralogy of Fallot (TOF) (Table 
2), with the highest risks for gastroschisis and spina bifida. The use of ibuprofen was 
associated with the same set of birth defects as the larger NSAID exposure group, except for 
cleft lip without cleft palate, which was associated with the use of aspirin (Table 3). Use of 
opioids was significantly associated with three heart defects: TOF, perimembranous 
ventricular septal defect (VSD), and VSD with atrial septal defect (ASD) (Table 2). The use 
of hydrocodone was associated with a similar set of heart defects, with the exclusion of VSD 
with atrial septal defect, and with two non-heart defects: cleft palate and cleft lip with cleft 
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palate. Codeine was associated with perimembranous VSD (Table 4). Periconceptional use 
of both opioids and NSAIDs was associated with three non-heart defects and two heart 
defects: gastroschisis, cleft palate, spina bifida, and hypoplastic left heart syndrome and 
PVS, respectively (Table 2).
In the sensitivity analyses where we excluded certain groups, the associations between 
NSAIDs and many selected birth defects remained fairly consistent (Supplemental Figure). 
However, a few slight changes were found in sensitivity analyses involving opioids, in which 
removing periconceptional surgery, fever, or nonanalgesic medication use led to increased 
risks for some birth defects. In the sensitivity analysis of gastroschisis, we found no 
evidence of an interaction between analgesic exposures and maternal age (data not shown). 
The most common questionnaire sections in which opioid use was reported related to 
procedures (23% each) and injuries (11% each), with a moderate portion “not specified” 
(37% and 41%, respectively) (data not shown). However, for those with a section specified 
(i.e., proxy for reason for analgesic use), there were no notable differences between mothers 
reporting opioids and those reporting both opioids and NSAIDs.
Conclusions
In this analysis, we found that approximately 80% of women reported analgesic use in 
pregnancy, with approximately 50%–60% reporting use periconceptionally. In addition, we 
found that compared to periconceptional use of acetaminophen, selected birth defects, both 
non-heart and heart, occurred more frequently among women reporting use of NSAIDs. The 
occurrence of selected birth defects was even higher among women reporting use of opioids. 
However, those associations were generally confined to selected heart defects among women 
reporting any opioid use, whereas the association with some non-heart defects was only seen 
among women reporting use of hydrocodone specifically. The associations we observed 
between opioids and birth defects persisted even when we removed individuals with surgery, 
fever, or use of other nonanalgesic medications, providing further support that these 
associations are more likely due to opioid medication use than the indications for use. The 
greatest occurrence of selected birth defects was among women reporting use of both 
opioids and NSAIDs. Although this finding could be due to an additive effect of the use of 
opioids and NSAIDs concurrently or due to increased analgesic exposure overall, the cause 
for this difference is unclear from our analyses and data available. However, it is unlikely 
that this difference is due to an increased severity of underlying illness among women 
reporting use of both opioids and NSAIDs as our findings did not vary greatly across the 
sensitivity analyses conducted.
No other studies that we are aware of have compared the use of analgesic medications to 
each other with respect to birth defect associations. Because many women need treatment 
for pain in pregnancy, this comparison of different pain management strategies is warranted. 
Comparing our study to previous literature is difficult because most studies that examined 
analgesic use in early pregnancy used an unexposed comparator, and many studies used the 
same data source and overlapping study population as this study, including Hernandez et al. 
[18], Lind et al. [32], Cleves et al. [17], and Broussard et al. [19]. However, these studies 
using the same data source analyzed data with EDDs up to 2007 while our study analyzed 
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data through 2011, adding 28% more cases and controls. In previous NBDPS analyses of 
NSAIDs, Hernandez et al. [18] found aspirin associated with anencephaly and cleft palate, 
ibuprofen with spina bifida and cleft lip with/without cleft palate, and naproxen with cleft lip 
with/without cleft palate; and Lind et al.’s [32] NBDPS analysis found ibuprofen associated 
with hypospadias. In this study, we also found associations between ibuprofen and spina 
bifida, cleft lip with cleft palate, and hypospadias. Cleves et al.’s [17] NBDPS study of 
muscular VSDs found no associations with first-trimester NSAID use (with or without the 
use of acetaminophen), similar to our negative finding. Broussard and colleagues’ [19] 
analyses of opioid use in NBDPS found significant associations with gastroschisis, any 
neural tube defect, spina bifida, PVS, and TOF. These results did not correspond to our 
findings for opioid use without NSAIDs, but rather with our findings for use of both opioids 
and NSAIDs, a distinction not made in their study.
In non-NBDPS studies, a few additional data sources have shown associations between 
NSAIDs and birth defects. In a Swedish cohort study, Ericson and Kallen [34] found early 
pregnancy naproxen use associated with orofacial clefts. In addition, a few studies found 
associations between aspirin and gastroschisis, including Werler et al. [26] using case-
control data from 15 cities across the United States and Canada, Torfs et al. [35] using data 
from the California Birth Defects Monitoring Program, and Drongowski et al. [36]. Our 
study did not find any associations between naproxen and selected birth defects and only 
saw a significant association between aspirin and cleft lip without cleft palate, which did not 
match findings from the previously mentioned studies. However, the naproxen association 
found by Ericson and Kallen [34] was based on only five exposed cases (compared to our 
81). The studies that found the aspirin association had various limitations. Werler et al. [26] 
was based on 13 exposed cases (compared to our 34), with a comparison group that included 
both malformed and nonmalformed controls, whereas Torfs et al. [35] was based on only 
seven exposed cases and Drongowski et al.’s [36] results were tentative because of high 
nonresponse and an unexpectedly high proportion of aspirin users in the case group. Using 
data from the Slone Epidemiology Center Birth Defects Study, Yadzy et al. [30] examined 
periconceptional opioid use, but the concomitant use of NSAIDs was not examined. 
Significant associations were found with gastroschisis, any neural tube defect, spina bifida, 
PVS, and TOF, which, as with the Broussard et al. [19] study, only correspond to our 
findings for use of both opioids and NSAIDs. Using data from the Baltimore–Washington 
Infant Study, Marsh et al.’s [14] study is the only other study that we are aware of that 
examined all three analgesics (acetaminophen, NSAIDs, and opioids) but, like other studies, 
used an unexposed comparator and only examined cardiovascular malformations. Marsh et 
al. [14] found non-salicylate NSAIDs associated with dextro-Transposition of the great 
arteries with intact ventricular septum, a category of heart defects that we were not able to 
examine. However, they did not find an association with dextro-Transposition of the great 
arteries in general, matching the findings of our study.
While this analysis utilized the largest U.S. population-based study of birth defects, with the 
ability to assess individual analgesics and individual birth defects, the study is subject to 
several important limitations. First, we lacked information on specific indication. While use 
of an active comparator attempted to reduce confounding by indication, as did our exclusion 
of specific groups in multiple sensitivity analyses, analgesics included in the analysis are 
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used for a variety of indications (pain, fever, inflammation, etc.) for which we were unable 
to completely account. Women may have been channeled by their physician to 
acetaminophen for more benign conditions given its perceived safety profile during 
pregnancy, whereas women taking NSAIDs and opioids may have had more serious or 
complex conditions or symptoms for which the benefit of these medications was perceived 
by the prescriber to outweigh any risks. Second, because analgesics are often used in 
combination with other analgesic and nonanalgesic medications, the effects of individual 
medications are hard to differentiate. Third, because exposure information was self-reported 
and could have occurred up to two years before interviews, recall is subject to 
misclassification. However, multiple questions were asked to determine medication use, and 
the self-reported nature provides information on actual consumption rather than prescription 
alone. Fourth, we were not able to assess dose or whether women took these medications 
during the critical time period relative to the defect of interest. Conversely, the long exposure 
risk window may lend itself to a dilution of potential teratogenic risk. Fifth, the analytic 
design of our study does not lend itself to assessment of risks associated with acetaminophen 
because we used it as the comparator; however, we did not see any effects of acetaminophen 
itself when compared to unexposed women using these data (Supplemental Table 1). Finally, 
because we conducted almost 600 statistical tests, we would expect approximately 30 
statistically significant results due to chance alone. However, we would not expect this 
random error to explain the disproportionate increased risks of heart-related defects 
observed primarily in opioid users.
In conclusion, we found that compared to periconceptional use of acetaminophen, selected 
birth defects occurred more frequently among women reporting use of NSAIDs and/or 
opioids. However, while many of the selected birth defects were associated with the use of 
NSAIDs, risks were small with a 1.5-fold increase, and while the use of both opioids and 
NSAIDs had a two- to three-fold increased risk for both non-heart and heart defects, these 
results translate to a modest increase in absolute risk. Moreover, it is unclear whether these 
increased associations are attributable to NSAIDs and/or opioids or to the indications for 
which these medications were taken. Pain management in pregnancy is important for the 
health of both the mother and fetus, and any pain management strategy considerations 
should weigh the risks and benefits for patients who are or may be pregnant. Future research 
should continue to compare the relative fetal safety of individual analgesics within these 
classes to help guide clinicians in the selection of safe and effective pain management 
strategies in pregnancy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Study selection flowchart, National Birth Defects Prevention Study 1997–2011. Flowchart 
showing exclusion criteria leading to final sample size included in this analysis. Ca. = cases; 
Co. = controls; B3–P9 = 3 months before conception through the end of pregnancy; B1–P3 
= 1 month before conception through third month of pregnancy; NSAIDs = nonsteroidal 
anti-inflammatory drugs; *After restricting to defects with positive associations with one or 
more of the analgesics of interest noted in previous studies.
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Fig. 2. 
Proportion of mothers reporting analgesic use, among mothers meeting initial inclusion 
criteria, from B3–P9, National Birth Defects Prevention Study 1997–2011. Line graph 
showing the proportion of mothers using specific analgesics by month of use among mothers 
who reported any use from 3 months before conception (B3) through the end of pregnancy 
(P9). Analgesic categories are not mutually exclusive.
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